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OBJECTIVE — The antidiabetic properties of metformin are mediated through its ability to
activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor
formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the
hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS — In an observational cohort study using
record-linkage databases and based in Tayside, Scotland, U.K., we identiﬁed people with type 2
diabetes who were new users of metformin in 1994–2003. We also identiﬁed a set of diabetic
comparators, individually matched to the metformin users by year of diabetes diagnosis, who
had never used metformin. In a survival analysis we calculated hazard ratios for diagnosis of
cancer, adjusted for baseline characteristics of the two groups using Cox regression.
RESULTS — Cancer was diagnosed among 7.3% of 4,085 metformin users compared with
11.6%of4,085comparators,withmediantimestocancerof3.5and2.6years,respectively(P
0.001). The unadjusted hazard ratio (95% CI) for cancer was 0.46 (0.40–0.53). After adjusting
for sex, age, BMI, A1C, deprivation, smoking, and other drug use, there was still a signiﬁcantly
reduced risk of cancer associated with metformin: 0.63 (0.53–0.75).
CONCLUSIONS — These results suggest that metformin use may be associated with a
reducedriskofcancer.Arandomizedtrialisneededtoassesswhethermetforminisprotectivein
a population at high risk for cancer.
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R
ecent research suggests that the an-
tidiabetic drug metformin, which
exerts its effects by activating the
AMP-activated protein kinase (AMPK),
may have potential for the treatment of
cancerinhumans(1).Thehypothesisthat
metformin may have anticancer effects is
supported by laboratory studies showing
thatmetforminisassociatedwithreduced
incidence of pancreatic cancer in ham-
sters(2)anddelaysonsetofmammary(3)
and other tumors (4) in tumor-prone
mice. Metformin also inhibits growth of
human breast cancer cells (5). Although




reduced risk of cancer among patients with
type 2 diabetes who had used metformin
(6). However, the outcome was limited to
hospitaladmissionsforcancer,andthedate
of diagnosis was assumed to be date of ﬁrst
hospital admission.
Other diabetic drugs may also have
cancer-related effects. An independent
epidemiological study found that users of
sulfonylureas were at higher risk of
cancer-related mortality than metformin
users (7). Sulfonylureas (and insulin)
increase circulating insulin levels, and
hyperinsulinemia may promote carcino-
genesis (8). Treatments such as met-
formin and glitazones reduce insulin
resistance, with insulin resistance possi-
bly associated with increased risk of can-
cer (9). The objective of this study was to
test the hypothesis that metformin use is
associated with a reduced risk of cancer in
peoplewithtype2diabetesusinganational
cancer registry to ensure valid diagnoses of
cancer with precise dates of diagnosis. We
also adjusted results for the effects of expo-
sure to other diabetic drugs.
RESEARCH DESIGN AND
METHODS— This observational his-
torical cohort study was carried out using
anonymous patient data for the resident
population of Tayside Health Board in
Scotland, U.K. (400,000 people). Data
were provided by the Health Informatics
Centre (HIC), University of Dundee,
whichhasdevelopedtherecordlinkageof
multiple routinely collected datasets for
research. Scottish Care Information–
Diabetes Collaboration (SCI-DC; for-
merly known as the Diabetes Audit and
Research in Tayside Scotland [DARTS]) is
a validated population-based diabetes
register with detailed clinical information
(10). A pharmacoepidemiological data-
base (formerly known as the Tayside
Medicines Monitoring Unit [MEMO]
drugsafetydatabase)holdscomputerized
records of every diabetic drug dispensed
to residents of Tayside, Scotland, U.K.,
since 1993 (11). Scottish Morbidity
Record 6 (SMR6) is a national database of
all diagnoses of cancer (12). Computer-
ized death certiﬁcation records from the
Registrar General with ICD9/ICD10-
coded causes of death (13,14) were also
available. All HIC data are anonymized
prior to analysis to maintain conﬁdential-
ity and conform to data protection
legislation.
The DARTS database was used to
identify patients who were diagnosed
with type 2 diabetes in Tayside, Scotland,
U.K., before 2004 (patients diagnosed
over the age of 35 years and younger pa-
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identiﬁed patients who received a ﬁrst
metforminprescriptionanytimebetween
1 January 1994 and 31 December 2003
(excluding patients who received met-
formin in 1993 or before diabetes diagno-
sis). We classiﬁed these patients as
metforminusersanddeﬁnedtheindexdate
as date of ﬁrst metformin prescription. Pa-
tients who had a record of cancer in SMR6
at any time between 1980 and the index
date were excluded.
Comparator patients individually
matched to the metformin users were
generated at random from a pool of pa-
tients with type 2 diabetes who had no
record of metformin use. We used a com-
puter algorithm that identiﬁed compara-
tors for each metformin user (listed in
random order). For each metformin user,
a potential comparator was identiﬁed
with the same year of diagnosis and as-
signed the same index date. Year of diag-
nosiswaschosenasamatchingvariableto
control for effects of treatment patterns
that could vary over time but not be mea-
sured directly. However, if there was a
record of cancer in SMR6 prior to the in-
dex date, or if they had died, the compar-
ator was discarded (but was potentially
available for a different metformin user).
This process was repeated until suitable
comparatorswereidentiﬁed.Thecompara-
tors who were identiﬁed for metformin us-
ers were therefore diagnosed with diabetes
in the same year and survived until the in-
dex date without cancer (the date that the
corresponding metformin user started
metformin). Any potential survival bias
(metforminuserssurvivingtogoontomet-
formin) was thus eliminated.
Baseline data were collated for all
metformin users and comparators: age at
index date, age at diagnosis of diabetes,
sex, smoking status, mean BMI and A1C
during the study period, and use of sulfo-
nylureas or insulin within 3 months or 1
year of the index date, respectively. An
area-based measure of material depriva-
tion (Carstairs score [15]) based on four
variables from the national census (car
ownership, unemployment, overcrowd-
ing,andhead-of-householdjobclassiﬁca-
tion) was also used.
Main outcome measures
We followed-up all patients from the in-
dex dates for predeﬁned outcomes. The
primary outcome was diagnosis of cancer
(as recorded in SMR6). Time to outcome
wasdeﬁnedastheperiodfromindexdate
to 1) date of diagnosis of cancer in SMR6,




We evaluated the risks of the following
secondary outcomes: diagnosis with
bowel cancer (ICD9 153–154, ICD10
C18–C20), lung cancer (ICD9 162,
ICD10 C33–C34), or breast cancer in
women (ICD9 174, ICD10 C50) as well
as all-cause mortality and mortality
from cancer (any mention on death
certiﬁcate).
Statistical methods
Time from index date to outcome in the
cohorts was shown using Kaplan-Meier
plots. The proportional hazards assump-
tion was examined using log (log) sur-
vival plots, with parallel lines indicating
that the assumption was reasonable. The
relationship between metformin use and
diagnosisofcancerwasassessedinanun-
adjustedCoxregressionanalysisandthen
in a multivariable model adjusted for age
at index date, sex, smoking status, depri-
vation, mean BMI and A1C during the
study period, and use of sulfonylureas
and insulin. These were all treated as cat-
egorical variables (as deﬁned in Table 1)
with the exception of A1C and BMI,
which were treated as continuous vari-
ables. The analyses were stratiﬁed by year
of diagnosis (the matching variable).
Dose-response analyses
For each metformin user, we identiﬁed
themaximummetformindoseprescribed
during follow-up. We then categorized
these as low dose (50% of maximum
prescribable dose), medium dose (50–
80%ofmaximumprescribabledose),and
high dose (80%). The risks associated
with each dose level were determined in a
stratiﬁed analysis with adjustments for all
covariates.However,incaseofconfound-
ing by duration of follow-up, we further
stratiﬁed patients according to length of
time in the study.
Ethical approval was obtained from
the multicenter research and ethics com-
mittee for Scotland.
RESULTS— There were 13,344 pa-
tients alive in January 1993 who were di-
agnosed with type 2 diabetes in Tayside,
Scotland, U.K., before 2004, of which
12,255 were eligible for the study. We
identiﬁed 5,183 patients who received a
ﬁrst prescription for metformin after
1994 and selected 4,944 for whom there
was no cancer diagnosis prior to met-
formin use. The remaining patients were
5,883 patients who received no met-
formin prescriptions between 1993 and
2004 and 1,189 patients who received a
prescription for metformin in 1993.
These latter patients were excluded as the
date of starting metformin was unknown
(no prescribing data available prior to
1993). Figure 1 shows how patients were
selected for the study.
Metformin users and comparators
The computer algorithm was used to
identify comparators for the 4,804 met-
formin users who were aged 35 years at
their index date. The comparators were
identiﬁed from the 5,773 patients who
were aged 35 years and had no record
of metformin use. A comparator was suc-
cessfully identiﬁed for 4,364 users (the
remaining440metforminusersforwhom
comparators could not be found were ex-
cluded). However, all further analyses
were restricted to the 4,085 metformin
users who had more than one prescrip-
tion for metformin and their respective
comparators.
Thebaselinecharacteristicsofthetwo
groups are presented in Table 1. Met-
formin users were younger than their
comparatorsandslightlymorelikelytobe
current smokers (although smoking sta-
tus was unavailable for about one-quarter
of study subjects). BMI and A1C values
were also unavailable for 3 and 9% of
study subjects, respectively, who were
therefore assigned the mean values. Met-
formin users had higher mean values of
BMI and A1C. There was a much higher
proportion of metformin users who were
treated with sulfonylureas within 3
months but a lower proportion who used
insulin within a year. These differences
were all statistically signiﬁcant.
Main outcome measures
Cancerwasdiagnosedamong297(7.3%)
of the metformin users during follow-up,
compared with 474 (11.6%) of the com-
parators. Median time to cancer was 3.5
years (interquartile range [IQR] 2.1–5.8)
for metformin users, compared with 2.6
years (1.2–4.1) for comparators. Figure 2
shows the Kaplan-Meier plot for diagno-
sis of cancer (log-rank test P  0.001).
The proportional hazards assumption
was met for all study subjects.
The unadjusted Cox regression anal-
ysis showed a statistically signiﬁcant re-
duction in the risk of cancer in the new
metformin users with a hazard ratio (HR)
Libby and Associates
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creased cancer risk was observed among
men and with increasing age. It also ap-
peared that higher BMI and A1C were as-
sociated with a reduced risk of cancer.
This is difﬁcult to explain but may be a
diagnostic bias, with high BMI and A1C
indicative of less frequent health care–
seeking behavior.
In the multivariable analysis, the
adjusted HR (95% CI) increased to 0.63
(0.53–0.75)formetforminusers.Never
and ex-smokers were at reduced risk of
cancer, but the reduced risks associated
with increased BMI and A1C were less
marked. No statistically signiﬁcant ef-
fects were observed for use of sulfonyl-
ureas or insulin.
Figure 1—Flowchart showing how metformin users and comparators were selected for the study.
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The unadjusted and adjusted risks of the
secondary outcomes are presented in Ta-
ble 2. Metformin users were at much
lowerriskofoverallmortalityandcancer-
related mortality than their comparators.
Overall, 14.9% of metformin users died,
compared with 34.8% of the comparators.
The median survival times were 3.6 years
(IQR 2.2–5.9) and 2.8 years (1.4–4.3), re-
spectively.Additionally,3.0%ofmetformin
users died from cancer, compared with
6.1% of comparators. Reduced risks of
magnitude similar to that for all cancers
were observed for bowel cancer, lung can-
cer, and breast cancer, although the results




the risks for low, medium, and high doses
stratiﬁedbylengthoffollow-upweresignif-
icantly different from each other (as indi-
cated by overlapping CIs), there was a clear
trend for metformin users to have a higher
risk of cancer in the ﬁrst 2 years of follow-
up.Afterthis,amongpatientswiththesame
duration of follow-up, the risk appeared to
be lower with the highest metformin doses.
CONCLUSIONS— This study sup-
ports the hypothesis that users of met-
formin are at lower risk of cancer
compared with people with type 2 diabetes
on other treatments. Fewer than 8% of a
cohort of metformin users were diagnosed
with cancer during a maximum of 10 years
offollow-up,comparedwith11%ofacom-
parator cohort of nonusers. The median
time to cancer was 3.6 years among met-
formin users, compared with 2.5 years
among comparators, and they also had re-
duced overall and cancer-related mortality.
This was an observational study;
therefore, we could not control for all dif-
ferences between study groups. Met-
formin users could have been at lower
baseline risk of cancer than the compara-
tors.Indeed,theywereyoungerthantheir
comparators (but mean BMI and A1C
were higher). Metformin users did seem
to be a different group clinically from
nonusers, with a much lower rate of mor-
tality (some of which could be explained
by lower risk of cardiovascular mortality
[16]). Although this limitation is inherent
in the observational nature of the study,
we adjusted results for known potential
confounders and there were sizable
changes to the risk estimates. There may
still have been residual confounding or
unknown confounders, but it is unlikely
that this could account for the entire 37%
reduced risk of cancer observed.
Adjusting for use of other diabetic
drugs was necessary because there was a
higher proportion of metformin users
whoweretreatedwithsulfonylureascom-
Table 1—Baseline characteristics and results of Cox regression analysis for incidence of cancer among metformin users and comparators
Metformin users Comparators Diagnosed cancer Unadjusted Adjusted*
Comparators 4,085 — 474 1.00 1.00
Metformin users — 4,085 297 0.46 (0.40–0.53) 0.63 (0.53–0.75)
Sex
Female 1,848 (45.9) 1,875 (45.2) 315 1.00 1.00
Male 2,237 (54.1) 2,210 (54.8) 456 1.26 (1.09–1.45) 1.37 (1.18–1.59)
Age (years)
35–55 1,001 (24.5) 533 (13.1) 51 1.00 1.00
56–63 964 (23.6) 647 (15.8) 138 2.72 (1.97–3.75) 2.66 (1.92–3.68)
64–69 865 (21.2) 691 (16.9) 160 3.40 (2.48–4.67) 3.13 (2.27–4.32)
70–76 781 (19.1) 939 (23.0) 205 4.61 (3.39–6.28) 4.09 (2.98–5.61)
77–100 474 (11.6) 1,275 (31.2) 217 5.95 (4.37–8.12) 4.86 (3.51–6.73)
Smoking status
Current 577 (14.1) 558 (13.7) 109 1.00 1.00
Ex-smoker 1,015 (24.9) 866 (21.2) 177 0.99 (0.78–1.26) 0.77 (0.60–0.98)
Never 1,637 (40.1) 1,411 (34.5) 271 0.87 (0.69–1.09) 0.75 (0.60–0.94)
Not known 856 (21.0) 1,250 (30.6) 214 1.19 (0.94–1.51) 0.91 (0.72–1.16)
Carstairs deprivation category
1 (least deprived) 224 (5.5) 206 (5.0) 46 1.00 1.00
2 805 (19.7) 902 (22.1) 162 0.75 (0.56–1.01) 0.74 (0.55–0.99)
3 1,129 (27.6) 1,171 (28.7) 223 0.80 (0.61–1.07) 0.82 (0.62–1.09)
4 458 (11.2) 488 (12.0) 99 0.78 (0.56–1.08) 0.81 (0.58–1.12)
5 521 (12.8) 457 (11.2) 77 0.66 (0.47–0.92) 0.69 (0.49–0.97)
6 603 (14.8) 579 (14.2) 106 0.71 (0.52–0.98) 0.79 (0.58–1.09)
7 (most deprived) 345 (8.5) 282 (6.9) 58 0.72 (0.50–1.04) 0.83 (0.58–1.19)
BMI 30.7  3.5 28.6  3.1 — 0.93 (0.91–0.95) 0.98 (0.96–1.00)
A1C (%) 7.9  1.0 7.2  1.2 — 0.77 (0.72–0.82) 0.91 (0.84–0.98)
Insulin use
No use 3,833 (93.8) 3,512 (86.0) 696 1.00 1.00
Use within 1 year 252 (6.2) 573 (14.0) 75 0.99 (0.85–1.15) 1.13 (0.97–1.33)
Sulphonylurea use
No use 2,196 (53.8) 1,996 (73.3) 483 1.00 1.00
Use within 3 months 1,889 (46.2) 1,089 (26.7) 288 1.00 (0.78–1.28) 1.12 (0.87–1.47)
Data are n, n (%), means  SD, or HR (95% CI). *Adjusted for all covariates.
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proportion treated with insulin. This
probably reﬂects the heterogeneity of the
pool of potential comparators. Patients
not treated with metformin will encom-
pass those who do not yet require oral
therapy as well as those who have pro-
gressedtoinsulinaftertreatmentwithsul-
fonylureas only. However, we found no
statistically signiﬁcant independent ef-
fects of sulfonylureas and insulin on risk
of cancer in the Cox regression analysis.
In contrast, men and older people were at
increased risk of cancer, as might be ex-
pected. The results were similar for spe-
ciﬁc cancer types.
In a dose-response analysis, met-
formin users appeared to have a higher
risk of cancer during the ﬁrst 2 years of
follow-up. This may be because patients
who begin treatment with metformin are
more likely to have cancer diagnosed be-
cause they have increasing contact with
health care professionals. In later years of
follow-up, high maximum doses of met-
formin were associated with the greatest




duce a survival bias, with higher doses spu-
riously associated with reduced cancer
because patients have survived to receive a
higherdose.Thisisthereasonforstratiﬁca-
tionbylengthoffollow-up(althoughresid-
ual confounding may still be present).
Within the known limitations of ob-
servational data, we are conﬁdent in our
study design and data sources. The data
sources used were independent of each
other, and they provided objective mea-
Figure 2—Kaplan-Meier plot with 95% CIs showing time to cancer among metformin users and
comparators.
Table 2—Unadjusted and adjusted HRs for secondary outcomes with adjusted HRs for incidence of cancer stratiﬁed by maximum prescribed
dose and duration of follow-up with comparators as the reference category
n (%) Unadjusted Adjusted*
Incidence of bowel cancer
Comparators 76 (1.9) 1.00 1.00
Users 40 (1.0) 0.41 (0.28–0.61) 0.60 (0.38–0.94)
Incidence of lung cancer
Comparators 58 (1.4) 1.00 1.00
Users 35 (0.9) 0.49 (0.32–0.74) 0.70 (0.43–1.15)
Incidence of breast cancer in women
Comparators 41 (2.2) 1.00 1.00
Users 24 (1.3) 0.44 (0.26–0.73) 0.60 (0.32–1.10)
Overall mortality
Comparators 1,422 (34.8) 1.00 1.00
Users 609 (14.9) 0.32 (0.29–0.35) 0.42 (0.38–0.47)
Mortality from cancer
Comparators 248 (6.1) 1.00 1.00
Users 123 (3.0) 0.48 (0.39–0.60) 0.63 (0.49–0.81)
Incidence of cancer 2 years follow-up* 2–4 years follow-up* 4 years follow-up*
Maximum prescribed dose during
follow-up (n)
Low (1,017) 3.15 (1.92–5.18) 0.99 (0.44–2.25) 0.16 (0.06–0.44)
Medium (2,090) 1.94 (1.20–3.13) 0.51 (0.31–0.82) 0.40 (0.27–0.60)
High (978) 2.76 (0.56–13.45) 0.28 (0.12–0.70) 0.15 (0.09–0.25)
Data are HR (95% CI) unless otherwise indicated. *Adjusted for age, sex, smoking, deprivation, BMI, A1C, insulin use, and sulphonylurea use.
Metformin and cancer
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betic population of Tayside, Scotland,
U.K., is well deﬁned, and the MEMO da-
tabase used to identify metformin users
has been widely used for drug safety re-
search (11). The likelihood of misclassiﬁ-
cation of metformin exposure due to data
error is low because we ensured that all
patients had multiple metformin pre-
scriptions. We were otherwise unable to
judge whether patients actually took the
metformin as prescribed, although we
knowthatthedrugwascollectedfromthe
pharmacies (11). We are conﬁdent that
we eliminated survival bias in our choice
of comparators. The national cancer reg-
istry (SMR6) was used to identify cancer
diagnoses.Speciﬁcityislikelytobehigher
than sensitivity in this register, but if any
cancerdiagnosesweremissed,thiswould
not occur differentially with respect to
metformin status.
This study has produced sufﬁcient
epidemiological evidence that metformin
reduces the risk of cancer to make further
investigation a high priority. A plausible
biological mechanism hinges on the dis-
covery that the upstream LKB1 regulator
of AMPK is a tumor suppressor and that
activation of AMPK by LKB1 plays an im-
portant role in inhibiting cell growth
when cellular energy levels are low (17).
Metformin activates AMPK by inhibiting
mitochondrial respiration and increasing
5-AMP, which enhances activation of
AMPK by LKB1 (1). The blood glucose–
lowering properties of metformin are me-
diated through AMPK restoring cellular
energy levels by phosphorylating regula-
tory proteins that lead to stimulation of
glucose uptake into muscle tissues as well
as inhibition of gluconeogenesis in the
liver. The anticancer properties of met-
formin are likely to be mediated by
AMPK’s ability to preserve cellular energy
levels by phosphorylating proteins such
as p27KIP and TSC2 that lead to inhibi-
tion of cell growth and proliferation sig-
naling networks (18,19).
PriortothediscoverythattheLKB1tu-
mor suppressor activated AMPK, there was
little interest in the role of AMPK in cancer.
However, the ability of AMPK to gauge and
control cellular energy places it in an ideal
position to ensure that cell growth and pro-
liferation is coupled to the availability of a
sufﬁcient supply of nutrients and energy.
Recent laboratory evidence showing that
three distinct drugs activate AMPK-delayed
tumorigenesis in tumor-prone mice sug-
gests that activators of AMPK could have
therapeuticbeneﬁtforthetreatmentofcan-
cer in humans (4). The protective effects of
metformin on cancer development could
potentially be rapid and may occur at quite
a late stage of cancer development. Treat-
ment of animal cells with metformin signif-
icantly activates the AMPK pathway within
30 min (20–22). Metformin also inhibits
growth of cancer cells (5) or mouse embry-
onic stem cells (4) within 1–2 days. We be-
lieve that there is now a strong case to
conduct a randomized trial to establish
whether metformin is protective in a popu-
lation at high risk for cancer.
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